{'fraction_non_alphanumeric': 0.022900763358778626, 'fraction_numerical': 0.0028625954198473282, 'mean_word_length': 5.396341463414634, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Serum N-acetyl-beta-D-glucoasminidase and circulating immune complex activities in systemic lupus erythematosus.

Systemic lupus erythematosus (SLE) is an autoimmune disease associated with the production of circulating immune complexes which are believed to contribute to the tissue damage. The mechanism of this damage in vivo is not yet established but in-vitro work indicates that these complexes (and also activated complement fragments, especially C3b) lead to the selective release of lysosomal enzymes from macrophages, which can then degrade tissue components.1 2 Preliminary studies in patients with active SLE seemed to suggest that, while the activity of a lysosomal marker enzyme, N-acetyl-fi-Dglucosaminidase (NAG) was frequently raised, the immune complex concentration in serum was not always raised above normal. We therefore decided to study the relation between these two activities in a patient presenting with acute SLE to see whether any correlation would be observed during the course of the disease in an individual patient.